- Home
- LENZ vs COYA Comparison
LENZ vs COYA Comparison
Compare LENZ & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LENZ | COYA |
|---|---|---|
| Founded | 2019 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.8M | 102.7M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LENZ | COYA |
|---|---|---|
| Price | $3.22 | $4.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $23.86 | $15.21 |
| AVG Volume (30 Days) | ★ 744.4K | 117.7K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $152.18 | $387.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $3.12 | $3.71 |
| 52 Week High | $32.92 | $6.81 |
Technical Indicators
Market Signals| Indicator | LENZ | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 34.38 |
| Support Level | N/A | $3.89 |
| Resistance Level | $6.11 | $5.17 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 13.89 | 5.73 |
Price Performance
Historical ComparisonAbout LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.